Business Context and Reporting Period
This Form 8-K was filed by Obalon Therapeutics, Inc. (not Vyome Holdings, Inc.) on December 15, 2018. The report details executive leadership transitions and associated compensatory arrangements effective January 2, 2019.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margins, debt, or liquidity metrics. It focuses exclusively on executive compensation adjustments.
Material Changes
The primary material change involves the appointment of Kelly Huang as Chief Executive Officer and the transition of Andrew Rasdal to Executive Chairman of the Board. Corresponding compensation changes include:
- Kelly Huang (CEO): Annual base salary increased from $432,000 to $475,000; target bonus opportunity increased from 55% to 60% of base salary.
- Andrew Rasdal (Executive Chairman): Annual base salary decreased from $650,000 to $325,000; eligibility for the 2019 executive bonus program was removed.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, management commentary on operations, or discussion of risks and contingencies beyond the specific personnel changes.
Investor Verification Points
- Confirm the effective date of Kelly Huang's appointment as CEO (January 2, 2019).
- Verify the specific reduction in Andrew Rasdal's compensation and loss of bonus eligibility.
- Note that the registrant is Obalon Therapeutics, Inc., not Vyome Holdings, Inc.